A-1331852

first-in-class, bioavailable BCL-XL inhibitor

oral efficacy in xenograft, led to ADC dev.

from SBDD of prior BH3 mimetics

ACS Med. Chem. Lett., Jul. 5, 2020

AbbVie, North Chicago, IL / Genentech

A-1331852 is a highly potent, orally bioavailable inhibitor of BCL-XL, blocking a protein-protein interaction resulting in tumor cell apoptosis. The compound was an important tool compound for understanding the…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks